Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

113.70USD
11:41am EDT
Change (% chg)

$-0.14 (-0.12%)
Prev Close
$113.84
Open
$113.95
Day's High
$114.23
Day's Low
$112.70
Volume
233,460
Avg. Vol
648,431
52-wk High
$157.02
52-wk Low
$109.12

ALXN.OQ

Chart for ALXN.OQ

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab... (more)

Overall

Beta: 1.51
Market Cap(Mil.): $25,563.52
Shares Outstanding(Mil.): 224.56
Dividend: --
Yield (%): --

Financials

  ALXN.OQ Industry Sector
P/E (TTM): 54.06 14.32 17.37
EPS (TTM): 2.11 -- --
ROI: 3.85 -7.73 -5.89
ROE: 5.64 -7.36 -5.30

BRIEF-Alexion Pharmaceuticals says long-term data confirm benefits of Strensiq

* Alexion Pharmaceuticals - long-term data confirm benefits of treatment with strensiq in adolescents and adults with hypophosphatasia through 5 years Source text for Eikon: Further company coverage:

May 15 2017

Brazilian police search Alexion offices in fraud probe

SAO PAULO Brazilian police searched the Sao Paulo offices of drugmaker Alexion Pharmaceuticals Inc on Monday as part of a probe into its relationship with a patient advocacy group accused of filing fraudulent lawsuits to spur drug purchases.

May 08 2017

UPDATE 2-Brazilian police search Alexion offices in fraud probe

SAO PAULO, May 8 Brazilian police searched the Sao Paulo offices of drugmaker Alexion Pharmaceuticals Inc on Monday as part of a probe into its relationship with a patient advocacy group accused of filing fraudulent lawsuits to spur drug purchases.

May 08 2017

BRIEF-Alexion Pharmaceuticals Q1 non-GAAP earnings per share $1.38

* Raises FY 2017 non-GAAP earnings per share view $5.10 to $5.30

Apr 27 2017

Alexion Pharma names former Baxalta chief Ludwig Hantson CEO

Alexion Pharmaceuticals Inc on Monday named former Baxalta CEO Ludwig Hantson to its top job, as the rare-disease drug maker seeks to regain investor confidence following the exit of top management.

Mar 27 2017

UPDATE 2-Alexion Pharma names former Baxalta chief Ludwig Hantson CEO

March 27 Alexion Pharmaceuticals Inc on Monday named former Baxalta CEO Ludwig Hantson to its top job, as the rare-disease drug maker seeks to regain investor confidence following the exit of top management.

Mar 27 2017

Alexion Pharma names former Baxalta head Ludwig Hantson CEO

March 27 Alexion Pharmaceuticals Inc said it named former Baxalta head Ludwig Hantson chief executive officer as the rare-disease drug maker looks to steady the ship following the exit of its top management.

Mar 27 2017

BRIEF-Alexion appoints Ludwig Hantson as chief executive officer

* Alexion appoints Ludwig Hantson, Ph.D., as chief executive officer

Mar 27 2017

BRIEF-Alexion submits application for soliris as treatment for refractory generalized myasthenia gravis

* Alexion submits application in Japan for soliris® (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gmg) Source text for Eikon: Further company coverage:

Mar 22 2017

BRIEF-Arbutus licenses LNP delivery technology to Alexion

* Arbutus licenses LNP delivery technology to Alexion for use in single messenger RNA product candidate

Mar 16 2017

More From Around the Web

Competitors

Earnings vs. Estimates